The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.
The US-based Australian sleep apnoea device giant has exceeded expectations with strong second quarter numbers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback